Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $56.40 Consensus Price Target from Analysts

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given an average recommendation of “Hold” by the seven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $56.40.

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Tuesday, April 21st. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Finally, Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research note on Saturday, April 4th.

Institutional Investors Weigh In On Plus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PSTV. Jane Street Group LLC purchased a new position in Plus Therapeutics in the 2nd quarter valued at approximately $41,000. Scientech Research LLC purchased a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the third quarter valued at $46,000. Geode Capital Management LLC raised its stake in shares of Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after acquiring an additional 589,544 shares in the last quarter. Finally, L1 Global Manager Pty Ltd purchased a new position in Plus Therapeutics in the fourth quarter valued at $1,167,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Stock Down 4.7%

Shares of NASDAQ PSTV opened at $4.08 on Thursday. The business’s 50 day moving average is $5.09 and its two-hundred day moving average is $6.54. Plus Therapeutics has a 52-week low of $2.90 and a 52-week high of $23.42. The firm has a market cap of $28.07 million, a price-to-earnings ratio of -1.77 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.20). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. Analysts anticipate that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.